Importantly, single-agent anti-PD-1 has demonstrated activity in isolated cases with GBM associated with germline mismatch repair deficiency30,31 and in newly diagnosed patients with MGMT methylated GBM treated in the neoadjuvant setting12. Here, MGMT is linked to glioblastoma.